Quidel Corporation (QDEL)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Quidel Corporation...

According to Benzinga Pro, during Q1, Quidel (NASDAQ:QDEL) earned $479.94 million, a 64.75% increase from the preceding quarter. Quidel ...

Quidel Corporation (Nasdaq: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc (“Ortho”) by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022.

RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (“Quidel”) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Com

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Guardant Health Inc (GH), where a total of 10,391 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 59.1% of GH's average daily trading volume over the past month of 1.8 million shares..

Quidel's (QDEL) robust performance across two of its product categories drives its first-quarter 2022 top line.

Quidel Corp's(NASDAQ: QDEL)Q1 sales more than doubled to $1 billion, beating the consensus of $890 million ...

Quidel (QDEL) delivered earnings and revenue surprises of 25.65% and 21.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Quidel (NASDAQ:QDEL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:10 PM. Here's what investors need to know about ...

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2022.

The Medical Product companies' quarterly results are likely to reflect base business recovery. Let's see how MCK, CAH and PODD are poised ahead of their earnings releases.

With its stock down 11% over the past month, it is easy to disregard Quidel (NASDAQ:QDEL). However, a closer look at...

Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.

Quidel (QDEL) closed at $104.52 in the latest trading session, marking a -1.32% move from the prior day.

In the latest trading session, Quidel (QDEL) closed at $113.95, marking a +1.29% move from the previous day.

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal first quarter 2022 financial results after market close on Wednesday, May 4, 2022.

In the latest trading session, Quidel (QDEL) closed at $112.50, marking a -0.51% move from the previous day.

Quidel's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Investors in Quidel Corp. (QDEL) saw new options begin trading this week, for the May 20th expiration..

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR Portfolio S&P 400 Mid Cap ETF (SPMD), we found that the implied analyst target price for the ETF based upon its underlying holdings is $56.55 per unit.

After several extremely volatile days, US equity futures are ending the week in the green with European equities snapping two days of declines sparked by the Fed's plan for aggressive monetary-policy tightening, and Asian stocks trading higher.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Harpoon Announces Departure ...

Quidel Corp(NASDAQ: QDEL)expects Q1 FY22 sales of $990 million - $1 billion, up 164% - 166% Y/Y, beating the consensus of ...

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects total revenues in the first quarter of 2022 to be in the range of $990 million to $1,000 million, or growth of 164% to 166% from the first quarter 2021 revenue of $375.3 million. COVID-19 product revenues in the first quarter of 2022 are expected to be approximately $836 million, composed of approximately $657 million in QuickVue® COVID-19 test revenue and approximately $138 million in Sofia® SARS antigen test revenue.

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

By avoiding memes and sticking to a long-term strategy, you can minimize your portfolio's risk.

Quidel (QDEL) closed the most recent trading day at $112.46, moving -0.3% from the previous trading session.

Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Active Factor Mid Cap ETF (AFMC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $29.18 per unit.

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed ...